UNH UnitedHealth Group : Bullish and Bearish Analyst Opinions

UnitedHealth has structural issues in Optum.

Insurers providing private Medicare Advantage plans rose after the U.S. agreed to boost 2027 payments by almost 2.5% more than the initial proposal. The rate increase may allow companies to expand margins next year if they continue reducing benefits and managing expenses. Positive for stock prices due to improved revenue outlook and relief from federal cost-cutting pressures. If companies fail to effectively manage expenses or benefit reductions, margin expansion might not materialize.

The US government finalized a +2.5% payment increase for private Medicare plans (Medicare Advantage) in 2027, an improvement over the initial proposal and above expectations of ~1%. This affects roughly half a trillion dollars in spending. The higher rate helps insurers cover rising healthcare costs, supporting profitability and sustainability of their Medicare businesses. A positive regulatory outcome for major managed care companies, driving significant pre-market share price gains (UnitedHealth +10%, CVS +5%). Political rhetoric from President Trump questioning affordability of Medicare/Medicaid could lead to future payment pressure.

The government finalized a 2.48% Medicare rate increase for 2027, far exceeding the 0.09% initial proposal. This higher-than-expected rate adds $13 billion in government payments to the industry, directly boosting revenue and allowing for margin expansion. The favorable rate update removes a major regulatory overhang, driving immediate upside for dominant Medicare Advantage players. Bipartisan political pressure to curb Medicare Advantage spending and stricter scrutiny on coding/risk adjustments.

The speaker explicitly stated UnitedHealth's stock was "going through the roof today" following the announcement of a 2.48% Medicare Advantage rate increase for 2027. The final rate was much better than the 0% initially feared, representing a positive expectation shock. Companies that remained in the Medicare Advantage market are positioned to benefit. LONG because the company is a direct, immediate beneficiary of the favorable rate decision, which secures its profitability in a key business line for the near term. Future administration policy aimed at aggressively dialing back program costs could pressure margins and lead to strategic pullbacks.

CMS finalized a 2.48% average rate increase for Medicare Advantage payments, projected to result in over $13 billion in additional payments to plans in 2027. This increase improves the revenue outlook for private insurers like UnitedHealth that manage Medicare Advantage plans, reversing previous negative sentiment and supporting stock recovery. The stock's 10% after-hours gain and author's positioning suggest a bullish reversal opportunity after a prolonged downturn. Rate increase may be fully priced in after the jump; regulatory or cost pressures could persist; broader market or sector headwinds.

UNH ripped ~12% after hours on news that CMS finalized a +2.48% Medicare Advantage payment rate for 2027, reversing prior fears of cuts. The community views this as a major positive catalyst that was oversold on the initial proposal, creating a sharp relief rally. Strong, news-driven momentum play likely to continue short-term as the overreaction corrects. Some comments express regret for missing the move; the pop may be an "after-hours liquidity event" that could cool.

A healthcare industry worker reports that United/Optum is blatantly denying obvious claims. This aggressive denial strategy is suspected to be a tactic to artificially beef up Q1 earnings numbers. Watch UNH for a potential Q1 earnings beat driven by suppressed payouts, but be wary of long-term blowback. Anecdotal evidence from a single user; potential regulatory scrutiny if claim denial practices are exposed.

UNH is trading near the $268-$272 range. The author views this specific price channel as a massive, unjustified discount. Buy UNH at $268-$272, or aggressively buy if it drops into the low $260s. Unspecified fundamental headwinds in the healthcare sector; broader market corrections.

UNH is exhibiting an inverse correlation to the broader market (green when market is red). This inverse behavior makes UNH a potential hedge against the ongoing market volatility and downtrends. UNH can be used as a volatility play or safe haven while the rest of the market struggles. The inverse correlation may not hold consistently, and sector-specific risks could impact UNH independently.

The author presents a high-conviction bullish view that UnitedHealth Group represents a rare long-term investment opportunity at current prices.

"We saw evidence that in Minneapolis there were Somali primarily illegal immigrants who were defrauding a Medicaid program that was meant to go to autistic children... they were claiming that their kids were actually autistic even though they weren't." The VP also states the task force will "stop the payments" to states with fraud and use "law enforcement options." A massive, high-profile federal crackdown on Medicaid fraud, with the threat of withholding payments, will create significant headline, regulatory, and reimbursement risk for Medicaid-focused managed care organizations (MCOs). States like Minnesota and California will be under intense scrutiny, potentially leading to audits, recoupments, and tighter enrollment/eligibility controls, which could pressure revenues and margins for companies with high Medicaid exposure. This is an AVOID recommendation due to increased regulatory and headline risk that could negatively impact sentiment and fundamentals for Medicaid-centric health insurers. The crackdown may be less effective or slower than promised. The focus may narrow to specific fraudulent providers rather than the managed care companies themselves.

"you look at the insurance sector, you look at periodically counseling to education, tuition and health care... clearly parts of the economy where inflation is real sticky and persistent." Companies in these specific service sectors possess immense pricing power. Because healthcare and insurance are essential services, consumers cannot easily substitute or cut back on them. Therefore, these companies can continue to raise prices and maintain margins even in a stagflationary environment, acting as inflation-pass-through vehicles. LONG. Healthcare and insurance providers offer defensive positioning with strong pricing power during periods of sticky services inflation. Regulatory intervention if price hikes become politically untenable, or a severe macroeconomic shock that forces mass defaults on premiums and elective services.

With the Medicare Advantage rates about to be get renegotiated here in a couple weeks... I'm just afraid that this thing is just too topsy turvy. Regulatory and rate pressures in the Medicare and Medicaid space create massive headline risk, which can trigger sudden and severe stock drops regardless of the company's overall quality. AVOID because the unpredictable nature of government rate negotiations makes the stock too dangerous to hold right now. Medicare Advantage rates come in better than expected, sparking a massive relief rally in managed care stocks.

Under my plan, I want to stop all payments to big insurance companies and instead give the money directly to the people so that they can buy their own healthcare. Managed care organizations derive a massive portion of their revenue and earnings from government-sponsored programs, including ACA subsidies, Medicare, and Medicaid. Cutting off direct federal payments to these insurers would severely compress their margins, disrupt their revenue base, and force a complete restructuring of the health insurance market. SHORT. The administration is actively targeting the profitability and government funding mechanisms of major managed care companies. Congress blocks the proposed healthcare overhaul, maintaining the status quo for managed care revenues and government subsidies.

Trump attacks the Affordable Care Act, stating he wants to "stop all payments to big insurance companies" and notes that "insurance companies own Democrats." He also touts "Most Favored Nation" clauses dropping drug prices by 80%. The removal of federal subsidies/payments is a direct hit to the revenue of managed care organizations (UnitedHealth, Humana). Simultaneously, aggressive price controls on drugs compress margins for the broader healthcare/pharma sector. SHORT Managed Care and Big Pharma. Congressional gridlock preventing the removal of subsidies.

Jeffries states a primary goal is to "extend the Affordable Care Act tax credits" and notes that "17 House Republicans joined us" previously, indicating a bipartisan path. The expiration of these credits would cause "tens of millions" to lose coverage or face higher premiums. Extending them ensures a stable customer base for Managed Care Organizations (UNH) and reduces uncompensated care costs for Hospital systems (HCA). The bipartisan nature suggests this subsidy is a durable policy tailwind. LONG Healthcare providers and insurers (XLV). If the shutdown persists or the "affordability agenda" fails, the credits could lapse, hurting enrollment numbers.

UNH is named as one of the heavily discussed stocks on the subreddit that has underperformed the broader market recently. The author's central question is whether this underperformance is a precursor to a future rebound, representing a classic value investing scenario. For investors who believe in UNH's fundamental strength, the recent period of lagging the S&P 500 could be a buying opportunity, provided they have a long-term view. Regulatory headwinds, margin pressures, or other industry-specific challenges could be the true cause of underperformance, leading to further downside.

Senator Marshall explicitly mentioned "clipping the wings of the Pharmacy Benefit Managers (PBMs)" and codifying "Trump Rx" / price transparency. PBMs (owned by major insurers like CVS, Cigna, UnitedHealth) rely on opaque pricing models for profit. Legislative momentum to force transparency or reduce their leverage acts as a regulatory headwind for these specific healthcare verticals. WATCH / AVOID PBM-exposed healthcare stocks. Gridlock in Congress prevents legislation from passing.

The administration is pushing a healthcare framework that looks to "shift federal subsidies from the insurance companies to consumers." Managed Care Organizations (MCOs) rely heavily on federal subsidies (Medicare Advantage, etc.) for margin. Direct-to-consumer subsidies bypass the insurers, potentially squeezing their margins and reducing their role as intermediaries. SHORT large cap insurers heavily exposed to government programs. The healthcare lobby is powerful and may water down or block the transfer of subsidy mechanics.

Schneider explicitly highlights the "extension of the premium tax subsidies" as a priority, warning that without it, "millions of families are seeing their insurance increase by $1,500 a month." These subsidies (enhanced ACA tax credits) are direct revenue drivers for Managed Care Organizations (MCOs) focused on the exchange market. Schneider's push indicates that Democrats will make extending these credits a non-negotiable condition in budget talks. If extended, enrollment numbers for Centene, Molina, and others remain robust; if they lapse, churn increases and revenue drops. LONG. The political pressure to avoid an $18k/year cost spike for voters is high, favoring an eventual extension which benefits ACA-heavy insurers. Republican opposition to "pandemic-era" subsidy extensions could lead to a lapse, crushing margins for exchange-focused insurers.

The President intends to "codify his health care framework that seeks to shift federal subsidies from health care companies to U.S. consumers." Managed Care Organizations (MCOs) and insurers rely heavily on government subsidies (particularly in Medicare Advantage). Shifting these funds directly to consumers bypasses the insurers, threatening their margins and revenue models. SHORT. This represents a structural change to healthcare funding flows detrimental to intermediaries. The complexity of healthcare reform often leads to watered-down implementation.

"I want to stop all payments to big insurance companies and instead give that money directly to the people... stock prices soared... like nothing else." The administration views the "middleman" model of Managed Care Organizations (MCOs) as the primary driver of healthcare inflation. Shifting federal subsidies (ACA/Medicare) directly to patients bypasses the insurers, threatening their revenue streams and margin compression. SHORT. The political target on the back of the insurance sector is now explicit policy. The lobby for healthcare insurers is powerful; implementation of direct payments may face logistical gridlock.

Under the "No Surprises Act," insurers are losing over 80% of arbitration cases to providers regarding out-of-network bills. This creates a structural headwind for margins as insurers are forced to pay higher rates than anticipated. Additionally, the State of the Union address is expected to target insurer profitability and affordability, adding headline risk. WATCH / AVOID. Regulatory relief or changes to the arbitration process could alleviate cost pressures.

Schiller advises that for Democrats to win, they must "zero in on core issues, health care affordability and individual security." If Democrats successfully consolidate their messaging around "health care affordability" heading into the midterms, this typically signals legislative pressure on drug pricing and insurance premiums. Watch for increased volatility or downside pressure in the Healthcare sector as political rhetoric heats up regarding price controls. Democrats fail to unify their message (as Schiller notes they often "find a way to lose"), leaving the sector untouched.

UnitedHealth is in a large Wave 4 distribution/correction. The stock is trading at the lower bound of its historical range. Technical analysis suggests a mean reversion to the median price (~$450) and potentially higher to complete the long-term Wave 5. Long. Regulatory changes in US healthcare; rising medical costs.

"I have watched our health insurance increase at roughly 8% a year for the last almost 10 years... The average premium for a health insurance plan across the United States... is $27,000." Sweet notes that these margins "are paying people's jobs" and the system is entrenched despite regulation. Persistent 8% annual inflation in premiums translates directly to compounding revenue growth for major health insurers and providers. The inability to fix the system implies pricing power remains with the incumbents. LONG Healthcare sector and major insurers who are passing these costs on to employers/consumers. Regulatory intervention or a complete overhaul of the US healthcare system (though the speakers deem this unlikely).

The administration proposed a "0.09% next year" payment increase. Holz notes investors were "positioning long thinking this was going to be a turnaround year," but now we are entering a "pocket now for a year, maybe two, in which earnings don't expand or grow." The macro environment for government-sponsored healthcare has shifted from a growth story to a stagnation story. While the stocks have dropped 20%, the fundamental driver for stock price appreciation (earnings growth) has been removed for the medium term. Buying the dip is premature because the capital will be tied up in a sector with no catalyst for 12-24 months. Do not buy the dip yet. The thesis has shifted from "turnaround" to "stagnation." The final ruling in April could be revised upward significantly, causing a relief rally (short squeeze).

1. THE FACT: Trump plans to meet with 14 insurance companies (including health, auto, home) to tell them to cut rates, threatening to "cut them out" if they don't. 2. THE BRIDGE: Direct presidential pressure to cut rates across the insurance sector, particularly health insurance, could significantly compress profit margins and negatively impact earnings for these companies. 3. THE VERDICT: Short or avoid health insurance companies and other insurance providers due to potential government-mandated rate cuts.

1. THE FACT: Identified $300 as a "DEEP Discount" price for UNH. 2. THE BRIDGE: The speaker is identifying this as a deep discount, implying it's a good entry point for a long position. 3. THE VERDICT: UNH at $300 is considered a deep discount for a long-term play.